Blue Trust Inc. Acquires 964 Shares of ADMA Biologics Inc $ADMA

Blue Trust Inc. grew its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 53.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,762 shares of the biotechnology company’s stock after purchasing an additional 964 shares during the quarter. Blue Trust Inc.’s holdings in ADMA Biologics were worth $50,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ADMA. Farther Finance Advisors LLC boosted its stake in shares of ADMA Biologics by 1,149.1% in the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 2,505 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of ADMA Biologics by 251.6% in the 1st quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 4,715 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of ADMA Biologics by 7.4% in the 1st quarter. Janney Montgomery Scott LLC now owns 70,991 shares of the biotechnology company’s stock valued at $1,408,000 after purchasing an additional 4,865 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in shares of ADMA Biologics in the 1st quarter valued at about $240,000. Finally, PFG Investments LLC boosted its stake in shares of ADMA Biologics by 0.6% in the 1st quarter. PFG Investments LLC now owns 222,809 shares of the biotechnology company’s stock valued at $4,421,000 after purchasing an additional 1,301 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $14.36 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The company has a market capitalization of $3.43 billion, a P/E ratio of 16.70 and a beta of 0.47. The company’s 50 day moving average price is $16.00 and its two-hundred day moving average price is $18.36. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. The firm had revenue of $121.98 million for the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period last year, the company posted $0.13 EPS. On average, analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of ADMA Biologics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $27.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.